Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKromek Regulatory News (KMK)

Share Price Information for Kromek (KMK)

Share Price is delayed by 15 minutes
Get Live Data
8.60    -0.35 (-4.00%)
Bid:
8.20
Ask:
9.00
Spread: 0.80 (9.756%)
Market Cap: £55.03m
KMK Live PriceLast checked at - London Stock Exchange

Intraday Kromek Share Chart

Contract Win and Update on Trading

22 Jul 2014 07:00

RNS Number : 9233M
Kromek Group PLC
22 July 2014
 



Embargoed until: 07.00, 22 July 2014

 

Kromek Group plc

("Kromek" or "the Company")

 

Contract Win and Update on Trading

 

Bottle Scanner Imaging Technology

 

Kromek (AIM: KMK.L), a supplier of patented radiation detection technologies to the medical, security and nuclear markets, is pleased to announce a significant contract win in the security market, providing its advanced bottle scanner technology to a number of airports in Asia. This initial contract is worth US$620,000, and its revenues are expected to be recognised in the current financial year ending 30 April 2015.

 

Kromek's bottle scanner makes use of multispectral x-ray technology to scan liquid, aerosol and gel containers being taken on to aeroplanes for the presence of dangerous liquids. The order will see Kromek's bottle scanners distributed across multiple airports. This latest contract is a further validation of Kromek's world leading technology in a security market that is expanding rapidly due to increased concerns about global security.

 

Unlike other bottle scanning technologies, Kromek's multispectral x-ray detection technology is suitable for integration in baggage scanning equipment as well as in the stand alone Bottle Scanner. This technology allows a possible pathway to cater for changing security threats, such as explosives concealed inside small electronic devices and laptops; a function which has already been successfully demonstrated.

 

Kromek offers unique technology platform solutions and end user products for the screening of nuclear materials, conventional explosive threats, IEDs and liquid explosives. Its work has been supported by the US Department of Homeland Security, UK Home Office and the European Commission. Kromek recently completed an EU funded project where it utilised its multispectral x-ray detectors and advanced algorithms inside a commercial checkpoint baggage screening system. The technology has been tested using ECAC standards for the screening of liquids and demonstrated ultra-low false alarm rates, a critical parameter for operational needs in airports.

 

Commenting on the contract win, CEO of Kromek Arnab Basu, said:

 

"Airport security needs to continue to develop and evolve to match increased threats posed by global terrorists. Kromek is proud to be at the leading edge of this market. Our bottle scanning technology has already been deployed in over 25 airports across the EU and Australia, and we are pleased to be now entering the Asian market, where we see considerable scope for growth, in addition to our continued effort in Europe and the rest of the world. The Company continues to innovate in response to the market's needs, and this contract endorses the commercial applications and superiority of our products.

 

"This initial contract win is in a new geographical market with considerable scope for future growth."

 

The Company will announce its Preliminary results for the year ended 30 April 2014, on Thursday 28 August 2014 and expects to report results in line with current market expectations.

 

 

-ends-

 

For further information, please contact:

 

Kromek Group plc

Arnab Basu, CEO

Derek Bulmer, CFO

 

Tel: 01740 626060

Panmure Gordon

As Nominated Adviser and Broker

Corporate Finance

Freddy Crossley

Broking

Charles Leigh-Pemberton

 

Tel: 020 7886 2500

Tavistock Communications

John West

Andrew Dunn

Tel: 020 7920 3150

 

 

About Kromek Group plc

 

Kromek Group plc is a UK technology company (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride ("CZT"). Using its core CZT technology Kromek designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.

 

The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

 

Kromek uses multiple technologies in its manufacturing processes, including the established methods of 'liquid phase' detector production, and also 'vapour phase' production methods, which allow the production of high quality, high performance detectors on an industrial scale. Kromek has an intellectual property portfolio of more than 250 pieces of IP.

The Group's business model provides a vertically integrated technology offering to customers, from the growth of CZT crystals to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").

 

The Board believes that the vertical integration offered by Kromek, combined with the benefit of 25 years of research into CZT production and the patents and trade secrets accumulated by the Group, are unparalleled in the market place.

 

The Group has operations in the UK, Germany and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.

 

Currently, the Group has over a hundred full time employees across its global operations.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCRBMPTMBMTBFI
Date   Source Headline
4th Jun 20267:00 amRNSGrant of Long-Term Incentives
2nd Jun 20267:00 amRNS-RLaunch of new interactive investor hub
1st Jun 20267:00 amRNSPDMR/Director Shareholding, Issue of Equity & TVR
12th May 20267:00 amRNSFull Year 2026 Trading Update
30th Apr 20262:30 pmRNSIssue of Equity, TVR & Extension of Options
9th Mar 20261:36 pmRNSDirector Share Purchase
9th Mar 20261:36 pmRNSDirector Share Purchase
20th Jan 20267:00 amRNSInterim Results
16th Dec 20257:00 amRNSNotice of Results
15th Dec 202512:27 pmRNSHolding(s) in Company
3rd Nov 202511:32 amRNSDirector Share Purchase
28th Oct 20257:00 amRNSGrant of Options, PDMR Dealings and TVR
27th Oct 20252:16 pmRNSResult of AGM
27th Oct 20257:00 amRNSPre-close Trading Statement
3rd Oct 202510:06 amRNSNotice of AGM and Publication of Annual Report
16th Sep 20257:00 amRNSFinal Results
11th Aug 20257:00 amRNSNew Biosecurity Award from UK MoD
28th Jul 20257:00 amRNS$5m received under Siemens Healthineers agreement
21st Jul 20257:00 amRNS£1.7m contract win under UK Government Framework
23rd Jun 202511:40 amRNS-RCapital Markets Day Presentation
18th Jun 20257:00 amRNSCapital Markets Day
16th Jun 20254:02 pmRNSHolding(s) in Company
9th Jun 20257:00 amRNSIssue of Equity and Total Voting Rights
3rd Jun 20251:53 pmRNSHolding(s) in Company
3rd Jun 20257:00 amRNSCapital Markets Day
28th May 20257:00 amRNSNew Nuclear Security Orders
8th May 20257:05 amRNSDirectorate Change
8th May 20257:00 amRNSFull Year 2025 Trading Update
17th Feb 20257:00 amRNS$25m received under Siemens Healthineers agreement
7th Feb 20251:49 pmRNSHolding(s) in Company
6th Feb 202512:35 pmRNSHolding(s) in Company
30th Jan 20257:01 amRNSInterim Results
30th Jan 20257:00 amRNSKromek Signs Agreements with Siemens Healthineers
13th Dec 202412:20 pmRNSResult of AGM
18th Nov 20247:00 amRNSNotice of AGM and Publication of Annual Report
28th Oct 20247:01 amRNSFinal Results and Publication of Annual Report
28th Oct 20247:00 amRNSFinancing Update
30th Sep 20247:00 amRNSUpdate on Full Year Results
23rd Sep 20247:00 amRNSKromek selected for UK Government Framework
16th Sep 20247:00 amRNSKromek awarded £2.0m contract from UK MOD
21st Aug 202410:14 amRNSHolding(s) in Company
7th Jun 20249:20 amRNSCancellation of outstanding Convertible Loan Notes
29th May 20247:00 amRNSFY 2024 Trading Update
25th Apr 20247:00 amRNSKromek receives new Nuclear Security contract
3rd Apr 20243:13 pmRNSDirector/PDMR Shareholding
26th Mar 20247:00 amRNSKromek receives $2.1m security screening order
6th Mar 20243:21 pmRNSHolding(s) in Company
4th Mar 202412:16 pmRNSHolding(s) in Company
4th Mar 202411:51 amRNSResult of General Meeting
5th Feb 202410:17 amRNSConversion of £1.5m of Convertible Loan Notes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.